Browse > Article
http://dx.doi.org/10.4062/biomolther.2015.154

Inhibition of Wnt Signaling by Silymarin in Human Colorectal Cancer Cells  

Eo, Hyun Ji (Department of Bioresource Sciences, Andong National University)
Park, Gwang Hun (Department of Bioresource Sciences, Andong National University)
Jeong, Jin Boo (Department of Bioresource Sciences, Andong National University)
Publication Information
Biomolecules & Therapeutics / v.24, no.4, 2016 , pp. 380-386 More about this Journal
Abstract
Silymarin from milk thistle (Silybum marianum) has been reported to show an anti-cancer activity. In previous study, we reported that silymarin induces cyclin D1 proteasomal degradation through NF-${\kappa}B$-mediated threonine-286 phosphorylation. However, mechanism for the inhibition of Wnt signaling by silymarin still remains unanswered. Thus, we investigated whether silymarin affects Wnt signaling in human colorectal cancer cells to elucidate the additional anti-cancer mechanism of silymarin. Transient transfection with a TOP and FOP FLASH luciferase construct indicated that silymarin suppressed the transcriptional activity of ${\beta}$-catenin/TCF. Silymarin treatment resulted in a decrease of intracellular ${\beta}$-catenin protein but not mRNA. The inhibition of proteasome by MG132 and $GSK3{\beta}$ inhibition by SB216763 blocked silymarin-mediated downregulation of ${\beta}$-catenin. In addition, silymarin increased phosphorylation of ${\beta}$-catenin and a point mutation of S33Y attenuated silymarin-mediated ${\beta}$-catenin downregulation. In addition, silymarin decreased TCF4 and increased Axin expression in both protein and mRNA level. From these results, we suggest that silymarin-mediated downregulation of ${\beta}$-catenin and TCF4 may result in the inhibition of Wnt signaling in human colorectal cancer cells.
Keywords
Silymarin; Wnt signaling; Cancer chemoprevention; Human colorectal cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Abenavoli, L., Capasso, R., Milic, N. and Capasso, F. (2010) Milk thistle in liver diseases: past, present, future. Phytother. Res. 24, 1423-1432.   DOI
2 Aberle, H., Bauer, A., Stappert, J., Kispert, A. and Kemler, R. (1997) ${\beta}$-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797-3804.   DOI
3 Ahnen, D. J., Wade, S. W., Jones, W. F., Sifri, R., Mendoza Silveiras, J., Greenamyer, J., Guiffre, S., Axilbund, J., Spiegel, A. and You, Y. N. (2014) The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin. Proc. 89, 216-224.   DOI
4 Amado, N. G., Fonseca, B. F., Cerqueira, D. M., Neto, V. M. and Abreu, J. G. (2011) Flavonoids: potential Wnt/beta-catenin signaling modulators in cancer. Life Sci. 89, 545-554.   DOI
5 Anderson, E. C., Hessman, C., Levin, T. G., Monroe, M. M. and Wong, M. H. (2011) The role of colorectal cancer stem cells in metastatic disease and therapeutic response. Cancers (Basel) 3, 319-339.   DOI
6 Behrens, J., von Kries, J. P., Kühl, M., Bruhn, L., Wedlich, D., Grosschedl, R. and Birchmeier, W. (1996) Functional interaction of bcatenin with the transcription factor LEF-1. Nature 382, 638-642.   DOI
7 Bos, J. L., Fearon, E. R., Hamilton, S. R., Verlaan-de Vries, M., van Boom, J. H., van der Eb, A. J. and Vogelstein, B. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293-297.   DOI
8 Cassileth, B. R. and Deng, G. (2004) Complementary and alternative therapies for cancer. Oncologist 9, 80-89.   DOI
9 Chastek, B., Kulakodlu, M., Valluri, S. and Seal, B. (2013) Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization. Postgrad. Med. 125, 73-82.
10 Cufi, S., Bonavia, R., Vazquez-Martin, A., Corominas-Faja, B., Oliveras-Ferraros, C., Cuyas, E., Martin-Castillo, B., Barrajon-Catalan, E., Visa, J., Segura-Carretero, A., Bosch-Barrera, J., Joven, J., Micol, V. and Menendez, J. A. (2013) Silibinin meglumine, a watersoluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food Chem. Toxicol. 60, 360-368.   DOI
11 Eo, H. J., Park, G. H., Song, H. M., Lee, J. W., Kim, M. K., Lee, M. H., Lee, J. R., Koo, J. S. and Jeong, J. B. (2015) Silymarin induces cyclin D1 proteasomal degradation via its phosphorylation of threonine-286 in human colorectal cancer cells. Int. Immunopharmacol. 24, 1-6.   DOI
12 Espada, J., Calvo, M. B., Diaz-Prado, S. and Medina, V. (2009) Wnt signalling and cancer stem cells. Clin. Transl. Oncol. 11, 411-427.   DOI
13 Fearon, E. R., Hamilton, S. R. and Vogelstein, B. (1987) Clonal analysis of human colorectal tumors. Science 238, 193-197.   DOI
14 Fodde, R., Smits, R. and Clevers, H. (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1, 55-67.   DOI
15 Kwon, I. K., Wang, R., Thangaraju, M., Shuang, H., Liu, K., Dashwood, R., Dulin, N., Ganapathy, V. and Browning, D. D. (2010) PKG inhibits TCF signaling in colon cancer cells by blocking ${\beta}$-catenin expression and activating FOXO4. Oncogene 29, 3423-3434.   DOI
16 Hawcroft, G., D'Amico, M., Albanese, C., Markham, A. F., Pestell, R. G. and Hull, M. A. (2002) Indomethacin induces differential expression of ${\beta}$-catenin, ${\gamma}$-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 23, 107-114.   DOI
17 Herbst, A. and Kolligs, F. T. (2007) Wnt signaling as a therapeutic target for cancer. Methods Mol. Biol. 361, 63-91.
18 Kaur, M., Velmurugan, B., Tyagi, A., Agarwal, C., Singh, R. P. and Agarwal, R. (2010). Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through downregulation of ${\beta}$-catenin-dependent signaling. Neoplasia 12, 415-424.   DOI
19 Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X. and He, X. (2002). Control of ${\beta}$-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837-847.   DOI
20 Lu, W., Lin, C., King, T. D., Chen, H., Reynolds, R. C. and Li, Y. (2012) Silibinin inhibits Wnt/${\beta}$-catenin signaling by suppressing Wnt coreceptor LRP6 expression in human prostate and breast cancer cells. Cell. Signal. 24, 2291-2296.   DOI
21 Luu, H. H., Zhang, R., Haydon, R. C., Rayburn, E., Kang, Q., Si, W., Park, J. K., Wang, H., Peng, Y., Jiang, W. and He, T. C. (2004) Wnt/${\beta}$-catenin signaling pathway as a novel cancer drug target. Curr. Cancer Drug Targets 4, 653-671.   DOI
22 Novo, M. C., Osugui, L., dos Reis, V. O., Longo-Maugeri, I. M., Mariano, M. and Popi, A. F. (2015) Blockage of Wnt/${\beta}$-catenin signaling by quercetin reduces survival and proliferation of B-1 cells in vitro. Immunobiology 220, 60-67.   DOI
23 Mereish, K. A., Bunner, D. L., Ragland, D. R. and Creasia, D. A. (1991) Protection against microcystin-LR-induced hepatotoxicity by Silymarin:biochemistry, histopathology, and lethality. Pharm. Res. 8, 273-277.   DOI
24 Narayan, S. (2004) Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting ${\beta}$-cateninmediated transactivation and cell-cell adhesion pathways. J. Mol. Histol. 35, 301-307.
25 Neergheen, V. S., Bahorun, T., Taylor, E. W., Jen, L. S. and Aruoma, O. I. (2010) Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology 278, 229-241.   DOI
26 Polakis, P. (2012) Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 4, a008052.
27 Ramasamy, K. and Agarwal, R. (2008) Multitargeted therapy of cancer by silymarin. Cancer Lett. 269, 352-362.   DOI
28 Reya, T. and Clevers, H. (2005) Wnt signalling in stem cells and cancer. Nature 434, 843-850.   DOI
29 Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2014) Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29.   DOI
30 Sparks, A. B., Morin, P. J., Vogelstein, B. and Kinzler, K. W. (1998) Mutational analysis of the APC/${\beta}$-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58, 1130-1134.
31 Xie, J., Xiang, D. B., Wang, H., Zhao, C., Chen, J., Xiong, F., Li, T. Y. and Wang, X. L. (2012) Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cells. PLoS One 7, e45617.   DOI
32 Tetsu, O. and McCormick, F. (1999) ${\beta}$-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426.   DOI
33 Vaid, M., Prasad, R., Sun, Q. and Katiyar, S. K. (2011) Silymarin targets ${\beta}$-catenin signaling in blocking migration/invasion of human melanoma cells. PLoS One 6, e23000.   DOI
34 Wang, D., Wise, M. L., Li, F. and Dey, M. (2012) Phytochemicals attenuating aberrant activation of ${\beta}$-catenin in cancer cells. PLoS One 7, e50508.   DOI
35 Yang, L. H., Xu, H. T., Han, Y., Li, Q. C., Liu, Y., Zhao, Y., Yang, Z. Q., Dong, Q. Z., Miao, Y., Dai, S. D. and Wang, E. H. (2010) Axin downregulates TCF-4 transcription via ${\beta}$-catenin, but not p53, and inhibits the proliferation and invasion of lung cancer cells. Mol. Cancer 9, 25.   DOI
36 Zi, X., Feyes, D. K. and Agarwa, R. (1998) Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDAMB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin. Cancer Res. 4, 1055-1064.